Delivery Order SPE2DB22D1017-SPE2DB25FH0CS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,203.06 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price contract, issued on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation, and performance will occur at...
- The Defense Logistics Agency awarded a $9,080.88 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA...
- The Defense Logistics Agency awarded a $27,880.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 5, 2025. This non-competitive delivery order represents a firm fixed-price purchase under the company's existing contract vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran...
- The Defense Logistics Agency awarded a $13,248.86 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick autoinjectors, with performance in Conshohocken, Pennsylvania and completion by August 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's broader pharmaceutical supply arrangements with the federal government. This delivery order falls under...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,783.70 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector medication, with an ultimate completion date of August 22, 2025. This non-set-aside contract was competitively awarded and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is the vendor's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $12,894 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pharmaceutical supplies. The contract, which was competitively awarded with no set-aside designation, has an ultimate completion date of September 9, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,757.77 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract was executed on August 21, 2025, with an ultimate completion date of August 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a $41,877.63 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens under a firm fixed price contract type. The award was made on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this transaction. This delivery order constitutes a...
- The Defense Logistics Agency awarded a $9,272.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens, with an ultimate completion date of September 4, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $1,126.53 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pharmaceutical products. This firm fixed price delivery order, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a competitively awarded, non-set-aside contract. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. As a child delivery order, this award falls...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FH0CSDelivery Order
The Defense Logistics Agency awarded a $1,135.11 firm fixed price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 20, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. Repatha is a specialty medication used for cholesterol management, reflecting the contractor's extensive portfolio spanning multiple therapeutic domains including diabetes treatments, neurological medications, pain management pharmaceuticals, and specialized medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/19/25 |